Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

3 Months Ended

Mar. 31, 2023

Accrued Expenses

Accrued Expenses

5Accrued Expenses

Accrued expenses consist of the following:


		March 31,			December 31,
		2023			2022
Accrued interest on preferred members’ interests		$	188,085		$	188,085
Accrued compensation			93,149			159,704
Accrued professional fees			69,300			11,600
Accrued director fees			46,500			31,000
Accrued clinical research costs			14,500			78,349
Other miscellaneous accrued expenses			2,662			1,360
		$	414,196		$	470,098